PL2900230T3 - Związki do leczenia otyłości i sposoby ich zastosowania - Google Patents

Związki do leczenia otyłości i sposoby ich zastosowania

Info

Publication number
PL2900230T3
PL2900230T3 PL13773562T PL13773562T PL2900230T3 PL 2900230 T3 PL2900230 T3 PL 2900230T3 PL 13773562 T PL13773562 T PL 13773562T PL 13773562 T PL13773562 T PL 13773562T PL 2900230 T3 PL2900230 T3 PL 2900230T3
Authority
PL
Poland
Prior art keywords
obesity
ways
compounds
treatment
application
Prior art date
Application number
PL13773562T
Other languages
English (en)
Inventor
Umut Ozcan
Joseph MAJZOUB
Ralph Mazitschek
Isin CAKIR
Serkan CABI
Original Assignee
The Children's Medical Center Corporation
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2900230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Children's Medical Center Corporation, The General Hospital Corporation filed Critical The Children's Medical Center Corporation
Publication of PL2900230T3 publication Critical patent/PL2900230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL13773562T 2012-09-27 2013-09-26 Związki do leczenia otyłości i sposoby ich zastosowania PL2900230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
EP13773562.7A EP2900230B1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2900230T3 true PL2900230T3 (pl) 2019-02-28

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13773562T PL2900230T3 (pl) 2012-09-27 2013-09-26 Związki do leczenia otyłości i sposoby ich zastosowania

Country Status (21)

Country Link
US (6) US9968575B2 (pl)
EP (3) EP2900230B1 (pl)
JP (2) JP6480864B2 (pl)
CN (3) CN104822374A (pl)
AU (3) AU2013323528B2 (pl)
BR (1) BR112015006848A2 (pl)
CA (2) CA2886393C (pl)
CY (1) CY1121166T1 (pl)
DK (1) DK2900230T3 (pl)
ES (1) ES2696626T3 (pl)
HR (1) HRP20181879T1 (pl)
HU (1) HUE040496T2 (pl)
LT (1) LT2900230T (pl)
PL (1) PL2900230T3 (pl)
PT (1) PT2900230T (pl)
RS (1) RS58010B1 (pl)
RU (2) RU2768868C2 (pl)
SI (1) SI2900230T1 (pl)
SM (1) SMT201800604T1 (pl)
TR (1) TR201815668T4 (pl)
WO (1) WO2014052583A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
EP3122347B1 (en) * 2014-03-26 2020-06-03 The Children's Medical Center Corporation Celastrol derivatives for the treatment of obesity
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
CN116133656A (zh) * 2021-09-09 2023-05-16 君德(新加坡)实验室有限公司 含脂肪酶抑制剂的高吸收性水凝胶
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
JPH11508895A (ja) 1995-06-30 1999-08-03 イーライ・リリー・アンド・カンパニー 糖尿病を処置する方法
CA2229450A1 (en) 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
DK0866720T3 (da) 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
CA2263826A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
HUP9904023A3 (en) 1996-09-20 2002-01-28 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type ii diabetes
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
ATE351910T1 (de) 1996-12-20 2007-02-15 Amgen Inc Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
IL133136A0 (en) 1997-06-06 2001-03-19 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ES2257287T3 (es) 1999-02-12 2006-08-01 Amgen Inc. Composiciones de leptina glicosiladas y metodos relacionados.
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc COMPOSITIONS FOR TREATING OR INHIBITING PATHOLOGICAL CONDITIONS IN CONNECTION WITH AN INFLAMMATORY ANSWER
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
EP1715539B1 (en) 2004-01-16 2012-11-07 Mitsubishi Materials Corporation Separator for fuel cell, method of producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
US8236769B2 (en) 2005-09-30 2012-08-07 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (en) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
EP2152252A4 (en) * 2006-11-13 2010-06-02 Univ Columbia SELECTIVE PROTEASOMIC INHIBITORS FOR THE TREATMENT OF DIABETES
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2705708A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
US9132108B2 (en) 2009-04-17 2015-09-15 Hiroshima University Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
AU2011292959B2 (en) 2010-08-23 2016-06-09 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
AU2013266086B2 (en) 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
HUE040496T2 (hu) * 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
EP3434268A1 (en) 2019-01-30
RU2018112067A3 (pl) 2021-06-24
CY1121166T1 (el) 2020-05-29
JP6743211B2 (ja) 2020-08-19
AU2013323528A1 (en) 2015-04-09
BR112015006848A2 (pt) 2018-05-22
ES2696626T3 (es) 2019-01-17
JP2019070052A (ja) 2019-05-09
RU2650646C2 (ru) 2018-04-16
CA3030272C (en) 2021-09-28
US20180185314A1 (en) 2018-07-05
CN111529534A (zh) 2020-08-14
US12064408B2 (en) 2024-08-20
PT2900230T (pt) 2018-11-26
US20170304245A1 (en) 2017-10-26
EP2900230B1 (en) 2018-08-15
EP4082541A1 (en) 2022-11-02
TR201815668T4 (tr) 2018-11-21
US11045439B2 (en) 2021-06-29
CA2886393C (en) 2019-02-26
JP2015531376A (ja) 2015-11-02
DK2900230T3 (en) 2018-11-12
AU2016247206A1 (en) 2016-11-10
AU2013323528B2 (en) 2016-11-10
CA3030272A1 (en) 2014-04-03
RU2768868C2 (ru) 2022-03-25
HUE040496T2 (hu) 2019-03-28
AU2016247206B2 (en) 2018-08-02
US20150250753A1 (en) 2015-09-10
AU2018256619A1 (en) 2018-11-22
SI2900230T1 (sl) 2019-01-31
HK1213190A1 (en) 2016-06-30
EP3434268B1 (en) 2022-04-20
SMT201800604T1 (it) 2019-01-11
CN111529535A (zh) 2020-08-14
CA2886393A1 (en) 2014-04-03
RU2018112067A (ru) 2019-03-07
US20210008019A1 (en) 2021-01-14
RU2015115696A (ru) 2016-11-20
US9968575B2 (en) 2018-05-15
WO2014052583A1 (en) 2014-04-03
JP6480864B2 (ja) 2019-03-13
US9925161B2 (en) 2018-03-27
US20210275482A1 (en) 2021-09-09
CN104822374A (zh) 2015-08-05
RS58010B1 (sr) 2019-02-28
LT2900230T (lt) 2019-01-10
US20250161252A1 (en) 2025-05-22
AU2018256619B2 (en) 2020-07-23
EP2900230A1 (en) 2015-08-05
US10653654B2 (en) 2020-05-19
HRP20181879T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
IL262956B (en) Methods for increasing efficacy of folr1 cancer therapy
IL282128A (en) Methods of treating overweight and obesity
LT2885010T (lt) Tautopatijos gydymo būdai
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
IL243976B (en) kdm1a inhibitors for disease treatment
LT2558105T (lt) Bardoksolono metilas, skirtas nutukimo gydymui
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP4144845C0 (en) ANTISENSE COMPOUNDS AND THEIR USES
PL2839230T3 (pl) Instalacja do obróbki obiektów
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
PL2900230T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP2887898A4 (en) Orthopedic fastener method
IL231092A0 (en) Treatment of rhinitis
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
DK2489413T5 (da) Behandlingsapparat
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
HUE045445T2 (hu) Kombinált terápia petefészekrák kezelésére
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
IL234606B (en) Novel methods and composition for treatment of disease
EP2415408A4 (en) Treatment device
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents